Neuromuscular blockers in early acute respiratory distress syndrome.

By L. Papazian, J. Forel, A. Gacouin, C. Penot-Ragon, G. Perrin, A. Loundou, S. Jaber, J. Arnal, D. Pérez, J. Seghboyan and 7 more. New England Journal of Medicine, 2010

2,039 citations recorded by the source corpus.

Subfields: Anesthesiology and Pain Medicine, Critical Care and Intensive Care Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/12c18bc6b468dfbd51698109d890383d4c2001c0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Anesthesiology and Pain Medicine

1. S. Mcgrane
2. Shruti B. Patel
3. Christopher G Hughes
4. J. Kress
5. Pratik Pandharipande

In Critical Care and Intensive Care Medicine

1. W. Organization
2. S. Mcgrane
3. Shruti B. Patel
4. Christopher G Hughes
5. J. Kress
6. Pratik Pandharipande

In Pulmonary and Respiratory Medicine

1. W. Organization
2. S. Mcgrane
3. Christopher G Hughes
4. J. Kress
5. Pratik Pandharipande
6. Arthur S Slutsky

Citations in the corpus

• Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. (2014, background): “Recently, positive impacts of neuromuscular blocking agents and prolonged prone-positioning sessions on 90-day survival were demonstrated by two landmark publications (31, 32).”
• Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. (2017, background): “Clinical data demonstrate that use of neuromuscular blocking agents decreases biotrauma (10) and improves physiological and clinical outcomes (11).”
• Sedation and analgesia in the mechanically ventilated patient. (2012, background): “The use of neuromuscular blocking agents has fallen out of favor because of evidence that they may contribute to prolonged neuromuscular weakness (39, 40); however, a study by Papazian and colleagues demonstrated that neuromuscular blockade may be useful in a select population of patients with early”
• Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance (2020, background): “Remark: A trial found that this strategy improved survival in adult patients with severe ARDS (PaO2/FiO2 < 150) without causing significant weakness (40), but results of a recent larger trial found that use of neuromuscular blockade with high PEEP strategy was not associated with a survival benefit ”
• Clinical review: intensive care unit acquired weakness (2015, result): “However, other prospective studies, of which some were randomized controlled trials, could not confirm such a role for corticosteroids [10, 13, 14, 18, 39, 40, 42–44, 46, 49] or for neuromuscular blocking agents [14, 50].”
• Sedation in the intensive care setting (2012, positive): “A recent multicenter randomized controlled trial demonstrated that early utilization of pharmacological paralysis decreased mechanical ventilation time and mortality in patients with acute respiratory distress syndrome without a witnessed increase in muscle weakness.(86) The results of this study ne”
• Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment (2018, background): “A single RCT demonstrated a mortality benefit in ARDS patients with a PaO2/FIO2 ratio less than 150 mmHg with the early use of a cisatracurium infusion for 48 hours with deep sedation compared with deep sedation alone.(79) The exact mechanism by which neuromuscular blockade is beneficial in patients”